213 related articles for article (PubMed ID: 35343198)
1. Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety.
Raja T; Sud R; Addla S; Sarkar KK; Sridhar PS; Talreja V; Jain M; Patil K
Indian J Cancer; 2022 Mar; 59(Supplement):S142-S159. PubMed ID: 35343198
[TBL] [Abstract][Full Text] [Related]
2. Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review.
Bolton EM; Lynch T
BJU Int; 2018 Sep; 122(3):371-383. PubMed ID: 29438592
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.
Shim M; Bang WJ; Oh CY; Lee YS; Cho JS
Investig Clin Urol; 2019 Jul; 60(4):244-250. PubMed ID: 31294133
[TBL] [Abstract][Full Text] [Related]
4. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
5. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
[TBL] [Abstract][Full Text] [Related]
6. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
[TBL] [Abstract][Full Text] [Related]
7. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
8. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
[TBL] [Abstract][Full Text] [Related]
9. [Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk : Comparative analysis against Leuprorelin by the Number Needed to Treat].
Anderson D; Lehmann J; Ecker T; Vosgerau S; Donatz V
Urologe A; 2017 Jul; 56(7):917-924. PubMed ID: 28405705
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: analysis of real-life data from Eudra-Vigilance and Food and Drug Administration databases entries.
Cicione A; Nacchia A; Guercio A; Gravina C; Franco A; Grimaldi MC; Tema G; Lombardo R; Tubaro A; De Nunzio C
Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):765-771. PubMed ID: 36641533
[TBL] [Abstract][Full Text] [Related]
11. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
[TBL] [Abstract][Full Text] [Related]
12. Luteinising hormone releasing hormone analogues in the treatment of prostate cancer.
Gommersall LM; Hayne D; Shergill IS; Arya M; Wallace DM
Expert Opin Pharmacother; 2002 Dec; 3(12):1685-92. PubMed ID: 12472366
[TBL] [Abstract][Full Text] [Related]
13. Relugolix: A Review in Advanced Prostate Cancer.
Shirley M
Target Oncol; 2023 Mar; 18(2):295-302. PubMed ID: 36652173
[TBL] [Abstract][Full Text] [Related]
14. Development of GnRH antagonists for prostate cancer: new approaches to treatment.
Cook T; Sheridan WP
Oncologist; 2000; 5(2):162-8. PubMed ID: 10794807
[TBL] [Abstract][Full Text] [Related]
15. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
[TBL] [Abstract][Full Text] [Related]
16. [Clinical study on the effectiveness and safety of combined laparoscopy and gonadotropin-releasing hormone agonist in the treatment of endometriosis].
Song JH; Lu H; Zhang J; Li B
Zhonghua Fu Chan Ke Za Zhi; 2013 Aug; 48(8):584-8. PubMed ID: 24199923
[TBL] [Abstract][Full Text] [Related]
17. Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
George DJ; Dearnaley DP
Future Oncol; 2021 Nov; 17(33):4431-4446. PubMed ID: 34409852
[TBL] [Abstract][Full Text] [Related]
18. External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens.
Cho E; Mostaghel EA; Russell KJ; Liao JJ; Konodi MA; Kurland BF; Marck BT; Matsumoto AM; Dalkin BL; Montgomery RB
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):236-43. PubMed ID: 25772183
[TBL] [Abstract][Full Text] [Related]
19. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy.
Gulley JL; Figg WD; Steinberg SM; Carter J; Sartor O; Higano CS; Petrylak DP; Chatta G; Hussain MH; Dahut WL
J Urol; 2005 May; 173(5):1567-71. PubMed ID: 15821487
[TBL] [Abstract][Full Text] [Related]
20. The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer.
Cirne F; Aghel N; Petropoulos JA; Klotz L; Lenihan DJ; Saad F; Pinthus J; Leong DP
Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):253-262. PubMed ID: 33470403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
